These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 9118820

  • 1. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 2. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC, Faulds D.
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [Abstract] [Full Text] [Related]

  • 3. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
    de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A.
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
    [Abstract] [Full Text] [Related]

  • 4. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM, Ormrod D.
    Drugs; 2002 May; 62(13):1909-44. PubMed ID: 12215067
    [Abstract] [Full Text] [Related]

  • 5. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T, Riesen WF, Keller U.
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [Abstract] [Full Text] [Related]

  • 6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Jul; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 7. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
    Spencer CM, Barradell LB.
    Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
    [Abstract] [Full Text] [Related]

  • 8. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A.
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [Abstract] [Full Text] [Related]

  • 9. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 10. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 11. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM, Croom KF.
    Drugs; 2007 Nov 14; 67(1):121-53. PubMed ID: 17209672
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE, Noll G, Hannak M, Lüscher TF.
    J Cardiovasc Pharmacol; 2000 Mar 14; 35(3):361-5. PubMed ID: 10710119
    [Abstract] [Full Text] [Related]

  • 13. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U.
    Lancet; 1996 Mar 30; 347(9005):849-53. PubMed ID: 8622389
    [Abstract] [Full Text] [Related]

  • 14. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS, Goa KL.
    Drugs; 2001 Mar 30; 61(12):1835-81. PubMed ID: 11693468
    [Abstract] [Full Text] [Related]

  • 15. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
    Gavish D, Leibovitz E, Shapira I, Rubinstein A.
    J Intern Med; 2000 May 30; 247(5):563-9. PubMed ID: 10809995
    [Abstract] [Full Text] [Related]

  • 16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 30; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 17. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ.
    Diabetes Metab Res Rev; 2000 Sep 30; 16(2):82-7. PubMed ID: 10751747
    [Abstract] [Full Text] [Related]

  • 18. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
    Papadakis JA, Milionis HJ, Press M, Mikhailidis DP.
    J Diabetes Complications; 2001 Sep 30; 15(4):211-26. PubMed ID: 11457674
    [Abstract] [Full Text] [Related]

  • 19. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH, Bachenheimer BS.
    Drugs; 2000 Jul 30; 60(1):55-93. PubMed ID: 10929930
    [Abstract] [Full Text] [Related]

  • 20. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire U, Hamsten A.
    J Am Coll Cardiol; 1998 Nov 15; 32(6):1648-56. PubMed ID: 9822092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.